Intrinsic Therapeutics announces that the AMA released the 2026 CPT code set, including the new CPT code 63032 describing bone-anchored annular closure, effective January 1, 2026

BOSTON, Oct. 24, 2025 /PRNewswire/ — Intrinsic Therapeutics, Inc., manufacturers of the Barricaid® annular closure device, today announced that the American Medical Association (AMA) has published a new Category I CPT® code, 63032, for the bone-anchored annular closure, effective January 1, 2026.

This new supplemental CPT code specifically describes the supplemental placement of a bone-anchored annular closure device (Barricaid) after lumbar discectomy in patients with large annular defects. The long descriptor for the CPT reads: “with repair of annular defect by implantation of a bone-anchored annular closure device, including all image guidance, 1 interspace, lumbar (list separately in addition to code for primary procedure).”

April Spillane, Vice President of Health Economics, said: “For more than twenty years, the spine community has sought effective solutions for discectomy patients at high risk of reherniation. This milestone marks an important step forward in advancing care for these patients. Surgeons will now be able to code the specific work of repairing an annular defect and implanting Barricaid after a discectomy. I have the sincere hope that this development will increase patient access to Barricada.”

Now that the ISASS 2025 guidelines recommend annular closure for appropriately selected patients, Intrinsic encourages surgeons and payers nationwide to update their systems to include this new 63032 code.

Greg Lambrecht, founder of Barricaid, went on to say, “This new CPT code is a recognition of the significant advancement Barricaid represents in the standard of care for discectomy patients. It is the result of the tremendous dedication of the Intrinsic team, specialty societies, and the spine surgeon community. I couldn’t be happier for the patients who now have a treatment pathway.”

About barricaid

Barricaid is a patented annular closure medical device designed to reduce re-operations for reherniations by 81%* in lumbar discectomy patients with large annular defects. Barricaid has been implanted in nearly 13,000 patients and is supported by clinical studies in eight different patient populations, including two randomized controlled trials and six single-arm studies. A level I multicenter RCT was published in JAMA demonstrating superior results to discectomy alone with five-year follow-up results.

*Some studies are outside of FDA indications. Values ​​at minimum 1 year postoperative. Minimum study size: 20 Barricaid subjects.

Barricaid is a registered trademark of Intrinsic Therapeutics, Inc.

CPT is a registered trademark of the American Medical Association (AMA).

SOURCE Intrinsic Therapeutics, Inc.